Medical Treatment in Ectopic Tubal Pregnancy

N/ACompletedNCT05208034

Nishtar Medical University100 enrolled

Overview

Ectopic pregnancy (EP) is estimated to be responsible for approximately 20% of all pregnancy-related mortality and 46% early pregnancy mortality.1 Hemodynamically stable women with EP are frequently managed with methotrexate (MTX) while multiple protocols like fixed multiple doses, single-dose as well as two-dose regimens have been in practice for treating EP, but no consensus exists regarding the optimum dosage regimen.

Literature reports multiple dosage regimens of MTX to be associated with increased rates of side effects. Single dose protocol has good compliance and fewer side effects but is linked with lower success rates in comparison to multiple dose protocols. A new treatment protocol involving "two-doses" of MTX for medical management of EP was introduced in 2007 but most of the research conducted so far has been retrospective in nature and limitations in study designs. No such study in recent years has been done in Pakistan to compare the success and safety of single-dose and two-dose MTX protocols so this study was planned to compare the success rates and safety of two-doses of MTX versus single dose of MTX in tubal EP.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

100

Conditions

Ectopic Pregnancy

Interventions

MethotrexateDRUG

Two-doses of intramuscular methotrexate as 50mg/m2.. One at at day-zero and 2nd at day 7.

Eligibility

Sex: FEMALEMin age: 20 YearsMax age: 35 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of tubal ectopic pregnancy. * Pre-treatment beta-human chorionic gonadotrophin (β-hCG) level below 1500 mIU/ml. * Gestational sac with largest diameter as 4cm. * Willing to take methotrexate treatment. * Willing to follow up. Exclusion Criteria: * Heterotrophic pregnancy * Persistent tubal pregnancy * Embryonic cardiac motion * Suspected tubal rupture * Past history of harmful effects of methotrexate treatment on organ functions.

Locations (1)

Nishtar Medical University Hospital

Multan Khurd, Pu, Pakistan

Outcomes

Primary Outcomes

success rate

In single-dose group,β-hCG levels were measured at day-4 and 7 and if β-hCG decreased \>15% between day-4 and day-7, the treatment was labeled successful. In two-dose group, in case 15% reduction in β-hCG level was observed at day-14, the treatment was labeled as success.

Time frame: 4-14 days

Secondary Outcomes

frequency of Side-effects of treatment

monitoring for the side effects during the treatment duration

Time frame: 1-14 days

β-hCG Resolution Time

Time taken for β-hcg resolution to reduce below 15%

Time frame: 1-14 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.